{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:08:28Z","timestamp":1793207308374,"version":"4.5.0"},"reference-count":158,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis US LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ard.2025.09.005","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T22:30:43Z","timestamp":1760653843000},"page":"6-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Understanding the immunopathophysiology of polymyalgia rheumatica: implications for treatment"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4459-8609","authenticated-orcid":false,"given":"Ernest H.","family":"Choy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8935-7473","authenticated-orcid":false,"given":"Sebastian H.","family":"Unizony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin F.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2534-550X","authenticated-orcid":false,"given":"Frank","family":"Buttgereit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2025.09.005_bib0001","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/art.30155","article-title":"The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases","volume":"63","author":"Crowson","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.09.005_bib0002","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/mr\/road026","article-title":"Clinical features of polymyalgia rheumatica patients in Japan: analysis of real-world data from 2015 to 2020","volume":"34","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0003","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/joim.13525","article-title":"An update on polymyalgia rheumatica","volume":"292","author":"Lundberg","year":"2022","journal-title":"J Intern Med"},{"key":"10.1016\/j.ard.2025.09.005_bib0004","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(17)31825-1","article-title":"Polymyalgia rheumatica","volume":"390","author":"Gonz\u00e1lez-Gay","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2025.09.005_bib0005","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1136\/annrheumdis-2018-213883","article-title":"Abdul Sultan A. Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study","volume":"77","author":"Partington","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.005_bib0006","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/acr.23132","article-title":"Epidemiology of polymyalgia rheumatica 2000-2014 and examination of incidence and survival trends over 45 years: a population-based study","volume":"69","author":"Raheel","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ard.2025.09.005_bib0007","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/art.22777","article-title":"Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica","volume":"57","author":"Hutchings","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.09.005_bib0008","doi-asserted-by":"crossref","first-page":"593","DOI":"10.4103\/ijmr.IJMR_298_17","article-title":"Diagnosis of polymyalgia rheumatica usually means a favourable outcome for your patient","volume":"145","author":"Milchert","year":"2017","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.ard.2025.09.005_bib0009","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/annrheumdis-2011-200329","article-title":"2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"71","author":"Dasgupta","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.005_bib0010","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.3899\/jrheum.190367","article-title":"Musculotendinous inflammation: the defining pathology of polymyalgia rheumatica?","volume":"46","author":"Owen","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0011","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/rheumatology\/keab506","article-title":"Ultrasound of shoulder and knee improves the accuracy of the 2012 EULAR\/ACR provisional classification criteria for polymyalgia rheumatica","volume":"61","author":"Kobayashi","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.09.005_bib0012","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1136\/annrheumdis-2024-eular.2433","article-title":"POS1460-HPR prevalence and management of patients with comorbidites and frailty in new onset polymyalgia rheumatica","volume":"83","author":"Sattui","year":"2024","journal-title":"Ann Rhem Dis"},{"key":"10.1016\/j.ard.2025.09.005_bib0013","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/rheumatology\/kep303a","article-title":"BSR and BHPR guidelines for the management of polymyalgia rheumatica","volume":"49","author":"Dasgupta","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.09.005_bib0014","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/ard-2023-225134","article-title":"Recommendations for early referral of individuals with suspected polymyalgia rheumatica: an initiative from the international giant cell arteritis and polymyalgia rheumatica study group","volume":"83","author":"Keller","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.005_bib0015","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","article-title":"2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.005_bib0016","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2011-200751","article-title":"Aortic stiffness is increased in polymyalgia rheumatica and improves after steroid treatment","volume":"71","author":"Schillaci","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.005_bib0017","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1080\/14397595.2020.1777680","article-title":"Predictors of long-term therapy with glucocorticoid in polymyalgia rheumatica","volume":"31","author":"Aoki","year":"2021","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0018","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10067-021-05819-z","article-title":"Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis","volume":"41","author":"Floris","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0019","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/ard-2023-224768","article-title":"Subclinical giant cell arteritis increases the risk of relapse in polymyalgia rheumatica","volume":"83","author":"De Miguel","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.005_bib0020","doi-asserted-by":"crossref","first-page":"rkac034","DOI":"10.1093\/rap\/rkac034","article-title":"Long-term use of glucocorticoids for polymyalgia rheumatica: follow-up of the PMR Cohort Study","volume":"6","author":"Muller","year":"2022","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.ard.2025.09.005_bib0021","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1136\/annrheumdis-2024-eular.1707","article-title":"AB1569-HPR clinical and economic burden of polymyalgia rheumtica in patients with an inadequate response to glucocorticoids or glucocorticoids taper in a real-world setting","volume":"83","author":"Curtis","year":"2024","journal-title":"Ann Rhem Dis"},{"issue":"suppl 9","key":"10.1016\/j.ard.2025.09.005_bib0022","article-title":"Changes in mortality risk after stopping glucocorticosteroids \u2013 a population-based study in rheumatoid arthritis","volume":"76","author":"Lacaille","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0023","doi-asserted-by":"crossref","first-page":"870","DOI":"10.7326\/M20-1594","article-title":"Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis: a cohort study","volume":"173","author":"George","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ard.2025.09.005_bib0024","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3899\/jrheum.110851","article-title":"Adverse events during longterm low-dose glucocorticoid treatment of polymyalgia rheumatica: a retrospective study","volume":"39","author":"Mazzantini","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0025","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/all.13556","article-title":"Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma","volume":"74","author":"Voorham","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.ard.2025.09.005_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.576134","article-title":"Frailty in rheumatic diseases","volume":"11","author":"Motta","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ard.2025.09.005_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2024.105730","article-title":"Recommendations of the French Society of Rheumatology for the management in current practice of patients with polymyalgia rheumatica","volume":"91","author":"Wendling","year":"2024","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ard.2025.09.005_bib0028","unstructured":"Sarilumab prescribing information [Internet]. [cited 2024 Jul 6]. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761037s015lbl.pdf"},{"key":"10.1016\/j.ard.2025.09.005_bib0029","unstructured":"Sarilumab summary of product characteristics [Internet]. [cited 2025 Mar 18]. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2024\/20241125164437\/anx_164437_en.pdf"},{"key":"10.1016\/j.ard.2025.09.005_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000694","article-title":"Polymyalgia rheumatica: an autoinflammatory disorder?","volume":"4","author":"Floris","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2025.09.005_bib0031","first-page":"S143","article-title":"Glucocorticoid treatment of polymyalgia rheumatica","volume":"29","author":"Caporali","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102670","article-title":"The pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle","volume":"19","author":"Carvajal Alegria","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ard.2025.09.005_bib0033","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4081\/reumatismo.2018.1048","article-title":"Pathogenesis of polymyalgia rheumatica","volume":"70","author":"Guggino","year":"2018","journal-title":"Reumatismo"},{"key":"10.1016\/j.ard.2025.09.005_bib0034","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/ard.56.10.576","article-title":"Genetic and environmental factors in polymyalgia rheumatica","volume":"56","author":"Cimmino","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.005_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102995","article-title":"Immune system activation in polymyalgia rheumatica: which balance between autoinflammation and autoimmunity? A systematic review","volume":"21","author":"Hysa","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ard.2025.09.005_bib0036","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s10067-023-06708-3","article-title":"Why is polymyalgia rheumatica a disease of older adults? Explanations through etiology and pathogenesis: a narrative review","volume":"43","author":"Coskun Benlidayi","year":"2024","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0037","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/ard.2006.051979","article-title":"Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis","volume":"65","author":"Cutolo","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.005_bib0038","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1093\/rheumatology\/keaa054","article-title":"Association of mucosal-associated invariant T cells with different disease phases of polymyalgia rheumatica","volume":"59","author":"Nakajima","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.09.005_bib0039","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(23)01310-7","article-title":"Polymyalgia rheumatica","volume":"402","author":"Esp\u00edgol-Frigol\u00e9","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2025.09.005_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1201575","article-title":"Aberrant phenotype of circulating antigen presenting cells in giant cell arteritis and polymyalgia rheumatica","volume":"14","author":"Reitsema","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ard.2025.09.005_bib0041","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1600-065X.2012.01146.x","article-title":"PAMPs and DAMPs: signal 0s that spur autophagy and immunity","volume":"249","author":"Tang","year":"2012","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ard.2025.09.005_bib0042","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1136\/annrheumdis-2012-201660","article-title":"NKG2D stimulated T-cell autoreactivity in giant cell arteritis and polymyalgia rheumatica","volume":"72","author":"Dejaco","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.005_bib0043","article-title":"B cells in rheumatoid arthritis: pathogenic mechanisms and treatment prospects","volume":"12","author":"Wu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ard.2025.09.005_bib0044","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1002\/art.38625","article-title":"Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica","volume":"66","author":"van der Geest","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0045","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/nrrheum.2017.51","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0046","article-title":"JAK signaling was involved in the pathogenesis of polymyalgia rheumatica","volume":"2022","author":"Yang","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.ard.2025.09.005_bib0047","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1186\/s13075-014-0492-2","article-title":"Interspinous bursitis is common in polymyalgia rheumatica, but is not associated with spinal pain","volume":"16","author":"Camellino","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"suppl 114","key":"10.1016\/j.ard.2025.09.005_bib0048","first-page":"86","article-title":"Use of contrast-enhanced magnetic resonance imaging of the pelvis to describe changes at different anatomic sites which are potentially specific for polymyalgia rheumatica","volume":"36","author":"Fruth","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0049","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/rheumatology\/keae043","article-title":"Musculoskeletal magnetic resonance imaging findings support a common spectrum of giant cell arteritis and polymyalgia rheumatica","volume":"64","author":"Seitz","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.09.005_bib0050","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2174\/1874312901105010100","article-title":"The normal synovium","volume":"5","author":"Smith","year":"2011","journal-title":"Open Rheumatol J"},{"issue":"suppl 5","key":"10.1016\/j.ard.2025.09.005_bib0051","doi-asserted-by":"crossref","first-page":"v3","DOI":"10.1093\/rheumatology\/kes113","article-title":"Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis","volume":"51","author":"Choy","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.09.005_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152527","article-title":"The immune pathology of bursitis in rheumatic inflammatory diseases, degenerative conditions and mechanical stress: a systematic review","volume":"68","author":"Zhang","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.09.005_bib0053","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.immuni.2017.01.004","article-title":"Autocrine loop involving IL-6 family member LIF, LIF receptor, and STAT4 drives sustained fibroblast production of inflammatory mediators","volume":"46","author":"Nguyen","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.ard.2025.09.005_bib0054","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ard.2025.01.004","article-title":"GM-CSF drives IL-6 production by macrophages in polymyalgia rheumatica","volume":"84","author":"Jiemy","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.005_bib0055","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/j.immuni.2023.06.012","article-title":"An autonomous activation of interleukin-17 receptor signaling sustains inflammation and promotes disease progression","volume":"56","author":"Luo","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.ard.2025.09.005_bib0056","unstructured":"Calabrese L, Spiera R. The new and evolving science of polymyalgia rheumatica unraveling PMR pathophysiology: the central role of IL-6 [Internet]. [cited 2025 May 5]. Available from: https:\/\/www.pmrandil6.com\/PMRPathophysiologyandIL-6Monograph.pdf"},{"key":"10.1016\/j.ard.2025.09.005_bib0057","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.943574","article-title":"Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumatica","volume":"13","author":"Reitsema","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ard.2025.09.005_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103589","article-title":"Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic literature review highlighting differences from the idiopathic forms","volume":"23","author":"Hysa","year":"2024","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ard.2025.09.005_bib0059","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/rheumatology\/keae099","article-title":"Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement","volume":"64","author":"Vermeulen","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.09.005_bib0060","first-page":"174","article-title":"Gastrointestinal disorders as immune-related adverse events","volume":"2","author":"Balducci","year":"2021","journal-title":"Explor Target Antitumor Ther"},{"key":"10.1016\/j.ard.2025.09.005_bib0061","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1122430","article-title":"Immune-related adverse events in checkpoint blockade: observations from human tissue and therapeutic considerations","volume":"14","author":"Williams","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ard.2025.09.005_bib0062","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000164393","article-title":"Proinflammatory cytokine profiles of patients with elderly-onset rheumatoid arthritis: a comparison with younger-onset disease","volume":"55","author":"Chen","year":"2009","journal-title":"Gerontology"},{"key":"10.1016\/j.ard.2025.09.005_bib0063","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/CIRCRESAHA.122.322128","article-title":"Immunology of giant cell arteritis","volume":"132","author":"Weyand","year":"2023","journal-title":"Circ Res"},{"key":"10.1016\/j.ard.2025.09.005_bib0064","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41584-023-00976-8","article-title":"Disease stratification in GCA and PMR: state of the art and future perspectives","volume":"19","author":"Tomelleri","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0065","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ard.2025.09.005_bib0066","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.mpmed.2018.01.008","article-title":"Clinical features of rheumatoid arthritis","volume":"46","author":"Gulati","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.ard.2025.09.005_bib0067","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1177\/014107680409700903","article-title":"Diagnosis of early rheumatoid arthritis: what the non-specialist needs to know","volume":"97","author":"Suresh","year":"2004","journal-title":"J R Soc Med"},{"key":"10.1016\/j.ard.2025.09.005_bib0068","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/art.1780370411","article-title":"HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid arthritis","volume":"37","author":"Weyand","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.09.005_bib0069","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1002\/art.22218","article-title":"Interleukin-10 promoter polymorphisms in giant cell arteritis","volume":"54","author":"Boiardi","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.09.005_bib0070","first-page":"2160","article-title":"Vascular endothelial growth factor gene polymorphisms in giant cell arteritis","volume":"30","author":"Boiardi","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0071","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1136\/annrheumdis-2013-203641","article-title":"Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis","volume":"72","author":"Serrano","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.005_bib0072","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.3390\/jcm11102905","article-title":"New insights into the pathogenesis of giant cell arteritis: mechanisms involved in maintaining vascular inflammation","volume":"11","author":"Greigert","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ard.2025.09.005_bib0073","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1093\/rheumatology\/kex391","article-title":"Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis","volume":"57","author":"Choy","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.09.005_bib0074","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/art.41774","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0075","unstructured":"Tocilizumab prescribing information [Internet]. [cited 2025 May 16]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125276s114lbl.pdf"},{"key":"10.1016\/j.ard.2025.09.005_bib0076","unstructured":"Upadacitinib prescribing information [Internet]. [cited 2025 May 16]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/211675s025lbl.pdf"},{"key":"10.1016\/j.ard.2025.09.005_bib0077","unstructured":"Methotrexate prescribing information [Internet]. [cited 2025 May 16]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/040054s015,s016,s017.pdf"},{"key":"10.1016\/j.ard.2025.09.005_bib0078","unstructured":"Leflunomide prescribing information [Internet]. [cited 2025 May 16]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/020905s033lbl.pdf"},{"key":"10.1016\/j.ard.2025.09.005_bib0079","unstructured":"Baricitinib prescribing information [Internet]. [cited 2025 May 16]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/207924s006lbl.pdf"},{"key":"10.1016\/j.ard.2025.09.005_bib0080","unstructured":"Rituximab prescribing information [Internet]. [cited 2025 May 16]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/103705s5453lbl.pdf"},{"key":"10.1016\/j.ard.2025.09.005_bib0081","unstructured":"Etanercept prescribing information [Internet]. [cited 2025 May 16]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/103795s5503lbl.pdf"},{"key":"10.1016\/j.ard.2025.09.005_bib0082","unstructured":"Infliximab prescribing information [Internet]. [cited 2025 May 16]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/103772s5412lbl.pdf"},{"key":"10.1016\/j.ard.2025.09.005_bib0083","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1136\/ard.60.11.1060","article-title":"Musculoskeletal manifestations in polymyalgia rheumatica and temporal arteritis","volume":"60","author":"Narv\u00e1ez","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.005_bib0084","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/rheumatology\/39.3.283","article-title":"The incidence and clinical characteristics of peripheral arthritis in polymyalgia rheumatica and temporal arteritis: a prospective study of 231 cases","volume":"39","author":"Gran","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.09.005_bib0085","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1136\/ard.60.11.1021","article-title":"Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study","volume":"60","author":"Caporali","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.005_bib0086","first-page":"506","article-title":"The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease","volume":"56","author":"Dejaco","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.09.005_bib0087","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.3390\/jcm11247412","article-title":"Predictive factors of giant cell arteritis in polymyalgia rheumatica patients","volume":"11","author":"Ramon","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ard.2025.09.005_bib0088","first-page":"179","article-title":"IL-6 promoter polymorphism at position -174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteritis","volume":"20","author":"Gonzalez-Gay","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0089","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2020.145070","article-title":"Assessment of interleukin 6 gene polymorphisms with rheumatoid arthritis","volume":"765","author":"Chen","year":"2021","journal-title":"Gene"},{"key":"10.1016\/j.ard.2025.09.005_bib0090","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3389\/fmed.2018.00364","article-title":"IL-17 in rheumatoid arthritis and precision medicine: from synovitis expression to circulating bioactive levels","volume":"5","author":"Robert","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ard.2025.09.005_bib0091","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/art.20001","article-title":"Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion","volume":"50","author":"Lubberts","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.09.005_bib0092","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/art.40070","article-title":"Secukinumab in active rheumatoid arthritis: a phase III randomized, double-blind, active comparator- and placebo-controlled study","volume":"69","author":"Blanco","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0093","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20192048","article-title":"Interleukin-17 in rheumatoid arthritis: trials and tribulations","volume":"217","author":"Taams","year":"2020","journal-title":"J Exp Med"},{"key":"10.1016\/j.ard.2025.09.005_bib0094","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.immuni.2008.10.011","article-title":"IRF-4-binding protein inhibits interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription factor","volume":"29","author":"Chen","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.ard.2025.09.005_bib0095","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2665-9913(23)00101-7","article-title":"Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Venhoff","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0096","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/OARRR.S291388","article-title":"Pain: a review of interleukin-6 and its roles in the pain of rheumatoid arthritis","volume":"13","author":"Sebba","year":"2021","journal-title":"Open Access Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0097","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.bbi.2006.10.010","article-title":"Interleukin-6 mediates low-threshold mechanical allodynia induced by intrathecal HIV-1 envelope glycoprotein gp120","volume":"21","author":"Schoeniger-Skinner","year":"2007","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.ard.2025.09.005_bib0098","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1017\/S1463423619000082","article-title":"The association of pain and stiffness with fatigue in incident polymyalgia rheumatica: baseline results from the polymyalgia rheumatica cohort study","volume":"20","author":"Prior","year":"2019","journal-title":"Prim Health Care Res Dev"},{"key":"10.1016\/j.ard.2025.09.005_bib0099","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/1744666X.2024.2306220","article-title":"Why does malaise\/fatigue occur? Underlying mechanisms and potential relevance to treatments in rheumatoid arthritis","volume":"20","author":"Tanaka","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.ard.2025.09.005_bib0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104402","article-title":"IL-6 involvement in pain, fatigue and mood disorders in rheumatoid arthritis and the effects of IL-6 inhibitor sarilumab","volume":"149","author":"Atzeni","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ard.2025.09.005_bib0101","first-page":"748","article-title":"Adrenal gland hypofunction in active polymyalgia rheumatica. Effect of glucocorticoid treatment on adrenal hormones and interleukin 6","volume":"29","author":"Cutolo","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0102","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1749-6632.2012.06634.x","article-title":"Role of interleukin-6 in stress, sleep, and fatigue","volume":"1261","author":"Rohleder","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"#cr-split#-10.1016\/j.ard.2025.09.005_bib0103.1","unstructured":"Nicolaides NC, Vgontzas AN, Kritikou I, Chrousos G. HPA Axis and Sleep. [Updated 2020 Nov 24]. In: Feingold KR, Ahmed SF, Anawalt B, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc."},{"key":"#cr-split#-10.1016\/j.ard.2025.09.005_bib0103.2","unstructured":"2000 [cited 2025 Oct 7]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/sites\/books\/NBK279071\/"},{"key":"10.1016\/j.ard.2025.09.005_bib0104","first-page":"655","article-title":"Polymyalgia rheumatica: evidence for a hypothalamic-pituitary-adrenal axis-driven disease","volume":"18","author":"Cutolo","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000084844","article-title":"IL-6 and its circadian secretion in humans","volume":"12","author":"Vgontzas","year":"2005","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.ard.2025.09.005_bib0106","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.bbi.2004.07.008","article-title":"The association between interleukin-6, sleep, and demographic characteristics","volume":"19","author":"Hong","year":"2005","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.ard.2025.09.005_bib0107","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.3390\/ijms21062194","article-title":"Role of interleukin-6 in depressive disorder","volume":"21","author":"Ting","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ard.2025.09.005_bib0108","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12974-021-02100-7","article-title":"On inflammatory hypothesis of depression: what is the role of IL-6 in the middle of the chaos?","volume":"18","author":"Roohi","year":"2021","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.ard.2025.09.005_bib0109","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ynstr.2016.03.003","article-title":"Integrating interleukin-6 into depression diagnosis and treatment","volume":"4","author":"Hodes","year":"2016","journal-title":"Neurobiol Stress"},{"key":"10.1016\/j.ard.2025.09.005_bib0110","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard-2022-223429","article-title":"Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica","volume":"83","author":"Dejaco","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.005_bib0111","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","article-title":"Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial","volume":"141","author":"Caporali","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ard.2025.09.005_bib0112","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/ard.55.4.218","article-title":"Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?","volume":"55","author":"van der Veen","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.005_bib0113","first-page":"624","article-title":"Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study","volume":"23","author":"Ferraccioli","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0114","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/ard.45.2.136","article-title":"Azathioprine in giant cell arteritis\/polymyalgia rheumatica: a double-blind study","volume":"45","author":"De Silva","year":"1986","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.005_bib0115","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/annrheumdis-2015-208742","article-title":"Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study","volume":"75","author":"Devauchelle-Pensec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.005_bib0116","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/annrheumdis-2021-221126","article-title":"Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2\/3 randomised controlled trial","volume":"81","author":"Bonelli","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.005_bib0117","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/jama.2022.15459","article-title":"Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial","volume":"328","author":"Devauchelle-Pensec","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ard.2025.09.005_bib0118","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJMoa2303452","article-title":"Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper","volume":"389","author":"Spiera","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.09.005_bib0119","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1111\/1756-185X.13723","article-title":"Tocilizumab monotherapy for polymyalgia rheumatica: a prospective, single-center, open-label study","volume":"22","author":"Chino","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.005_bib0120","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/art.39740","article-title":"Brief report: a prospective open-label phase IIa trial of tocilizumab in the treatment of polymyalgia rheumatica","volume":"68","author":"Lally","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0121","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004249","article-title":"Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica (EAST PMR): an open-label randomized controlled trial","volume":"20","author":"Ma","year":"2023","journal-title":"PLoS Med"},{"key":"10.1016\/j.ard.2025.09.005_bib0122","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1016\/S2665-9913(24)00270-4","article-title":"Baricitinib in early polymyalgia rheumatica (BACHELOR): a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"7","author":"Saraux","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0123","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/ard-2022-223562","article-title":"Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica: a phase 2 study","volume":"82","author":"Zhang","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.09.005_bib0124","doi-asserted-by":"crossref","first-page":"631","DOI":"10.7326\/0003-4819-146-9-200705010-00005","article-title":"Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial","volume":"146","author":"Salvarani","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ard.2025.09.005_bib0125","doi-asserted-by":"crossref","first-page":"R176","DOI":"10.1186\/ar3140","article-title":"Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial","volume":"12","author":"Kreiner","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ard.2025.09.005_bib0126","doi-asserted-by":"crossref","first-page":"e758","DOI":"10.1016\/S2665-9913(21)00245-9","article-title":"Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial","volume":"3","author":"Marsman","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0127","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(23)00032-2","article-title":"1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial","volume":"5","author":"Bolhuis","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0128","doi-asserted-by":"crossref","first-page":"e728","DOI":"10.1016\/S2665-9913(23)00246-1","article-title":"Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial","volume":"5","author":"Saraux","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0129","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/art.43129","article-title":"Efficacy, safety, pharmacokinetics, and immunogenicity of ABBV-154 in adults with glucocorticoid-dependent polymyalgia rheumatica: a phase 2, randomized, double-blind, placebo-controlled trial","volume":"77","author":"Spiera","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0130","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1111\/imj.14779","article-title":"Efficacy of methotrexate in polymyalgia rheumatica in routine rheumatology clinical care","volume":"50","author":"Ruediger","year":"2020","journal-title":"Intern Med J"},{"key":"10.1016\/j.ard.2025.09.005_bib0131","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/ggi.13460","article-title":"Retrospective analysis of the usefulness of a protocol with high-dose methotrexate in polymyalgia rheumatica: results of a single-center cohort of 100 patients","volume":"18","author":"Quartuccio","year":"2018","journal-title":"Geriatr Gerontol Int"},{"key":"10.1016\/j.ard.2025.09.005_bib0132","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00296-020-04783-2","article-title":"Effect of add-on methotrexate in polymyalgia rheumatica patients flaring on glucocorticoids tapering: a retrospective study","volume":"41","author":"Marsman","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ard.2025.09.005_bib0133","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1097\/RHU.0000000000001414","article-title":"Usefulness of methotrexate in the reduction of relapses and recurrences in polymyalgia rheumatica: an observational study","volume":"26","author":"de la Torre","year":"2020","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0134","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1742-1241.2012.02981.x","article-title":"Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series","volume":"66","author":"Adizie","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ard.2025.09.005_bib0135","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/120638","article-title":"Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series","volume":"2013","author":"Diamantopoulos","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ard.2025.09.005_bib0136","doi-asserted-by":"crossref","first-page":"rkae033","DOI":"10.1093\/rap\/rkae033","article-title":"Effectiveness of methotrexate and leflunomide as corticoid-sparing drugs in patients with polymyalgia rheumatica","volume":"8","author":"Vinicki","year":"2024","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.ard.2025.09.005_bib0137","article-title":"Effectiveness of IL-6 receptor inhibitors versus methotrexate or any conventional immunomodulators in patients with steroid refractory polymyalgia rheumatica","author":"Curtis","year":"2024","journal-title":"Congress of Clinical Rheumatology-East (CCR-E) poster presentation"},{"key":"10.1016\/j.ard.2025.09.005_bib0138","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/annrheumdis-2024-eular.1717","article-title":"POS1427 effectiveness of interleukin-6 receptor inhibitors versus conventional synthetic immunomodulatory therapy for treatment of frail patients with polymyalgia rheumtica","volume":"83","author":"Sattui","year":"2024","journal-title":"Ann Rhem Dis"},{"key":"10.1016\/j.ard.2025.09.005_bib0139","first-page":"1556","article-title":"AB0705 long term safety of conventional and biologic IL-6RI immunomodulators as second-line (2L) or third-line (3L) treatment of polymyalgia rheumatica","volume":"82","author":"Dikranian","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"suppl 9","key":"10.1016\/j.ard.2025.09.005_bib0140","article-title":"Comparative effectiveness of sarilumab vs. methotrexate as a glucocorticoid-sparing agent in patients with polymyalgia rheumatica","volume":"76","author":"Curtis","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0141","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/annrheumdis-2024-eular.2140","article-title":"POS0926 Real-world effectiveness and safety of tocilizumab in patients with polymylalgia rheumatica","volume":"83","author":"Imai","year":"2022","journal-title":"Ann Rhem Dis"},{"key":"10.1016\/j.ard.2025.09.005_bib0142","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1093\/rheumatology\/kead426","article-title":"Efficacy and management of tocilizumab in polymyalgia rheumatica: results of a multicentre retrospective observational study","volume":"63","author":"Assaraf","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.09.005_bib0143","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.2147\/IJGM.S414267","article-title":"Efficacy of JAK inhibitors versus DMARDs in the treatment of polymyalgia rheumatica in China","volume":"16","author":"Gu","year":"2023","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.ard.2025.09.005_bib0144","unstructured":"NCT03576794 [Internet]. [cited 2024 Jun 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03576794?term=NCT03576794&rank=1"},{"key":"10.1016\/j.ard.2025.09.005_bib0145","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/13543784.2024.2366847","article-title":"Investigational agents for polymyalgia rheumatica treatment: assessing the critical needs for future development","volume":"33","author":"Iorio","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ard.2025.09.005_bib0146","doi-asserted-by":"crossref","first-page":"e544","DOI":"10.1016\/S2665-9913(25)00041-4","article-title":"Sarilumab in relapsing polymyalgia rheumatica: patient-reported outcomes from a phase 3, double-blind, randomised controlled trial","volume":"7","author":"Strand","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ard.2025.09.005_bib0147","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3390\/jpm12030329","article-title":"The role of tumor necrosis factor alpha antagonists (Anti TNF-\u03b1) in personalized treatment of patients with isolated polymyalgia rheumatica (PMR): past and possible future scenarios","volume":"12","author":"Manzo","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.ard.2025.09.005_bib0148","unstructured":"Abatacept Prescribing Information [Internet]. [cited 2025 May 12]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125118s240lbl.pdf"},{"key":"10.1016\/j.ard.2025.09.005_bib0149","series-title":"VK.23. A type 1 11\u03b2-hydroxysteroid dehydrogenase inhibitor to optimize the effects of prednisolone in patients with polymyalgia rheumatica (PMR)","author":"Buttgereit","year":"2024"},{"key":"10.1016\/j.ard.2025.09.005_bib0150","unstructured":"NCT06130540 [Internet]. [cited 2024 Jun 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06130540?term=NCT06130540&rank=1"},{"key":"10.1016\/j.ard.2025.09.005_bib0151","unstructured":"NCT05436652 [Internet]. [cited 2024 Jun 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05436652?term=NCT05436652&rank=1"},{"key":"10.1016\/j.ard.2025.09.005_bib0152","unstructured":"NCT04062006 [Internet]. [cited 2024 Jul 6]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04062006?term=NCT04062006&rank=1."},{"key":"10.1016\/j.ard.2025.09.005_bib0153","unstructured":"NCT05767034 [Internet]. [cited 2024 Jun 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05767034?term=NCT05767034&rank=1."},{"key":"10.1016\/j.ard.2025.09.005_bib0154","unstructured":"NCT06331312 [Internet]. [cited 2025 Jun 4]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06331312?term=NCT06331312&rank=1"},{"key":"10.1016\/j.ard.2025.09.005_bib0155","unstructured":"NCT05533125 [Internet]. [cited 2024 Jun 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05533125?term=NCT05533125&rank=1"},{"key":"10.1016\/j.ard.2025.09.005_bib0156","unstructured":"NCT05533164 [Internet]. [cited 2024 Jun 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05533164?term=NCT05533164&rank=1"},{"key":"10.1016\/j.ard.2025.09.005_bib0157","unstructured":"NCT06172361 [Internet]. [cited 2024 Jun 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06172361?term=NCT06172361&rank=1"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725043869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725043869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T09:15:15Z","timestamp":1771492515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725043869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":158,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0003496725043869"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.09.005","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding the immunopathophysiology of polymyalgia rheumatica: implications for treatment","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}